Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 466

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 466
---
   |
| Net increase (decrease) in cash and cash equivalents |     |               3,142,026 |   |     | (2,908,764 | ) |

Contractual Obligations and Commitments OSR Holdings and its subsidiaries have entered into various contractual arrangements that involve future payments, such as on leases, clinical trials, other R&D activities and minimum purchases of medical devices (for resale). New OSR Holdings’ obligations for those payments in 2024, which vary in time and amount, are currently expected to be approximately KRW 7.55 billion. Those contracts for which the amount payable pursuant to the contract exceeds 5.0% of OSR Holdings revenues are described in the following table.

| Name of Party       |     |        Amounts Due 
 (KRW in thousands) |     | Due Dates |     | Termination date |     | Description and Material terms                                                            |
| Biotoxtech          |     |            800,000 |     | N/A       |     | 12/31/2025       |     | Pre-clinical studies of DRT – 101; payment schedule varies on clinical progress           |
| Microport Neurotech |     |          1,360,000 |     | N/A       |     | 12/31/2025       |     | Distribution agreement; Payment schedule varies on order (60 days after invoice issuance) |

The remaining contractual obligations relate to leases, accounting and related services. Storage, insurance, and other expenses (see Note 25 to the financial statements). Foreign Currency Exchange Risk Our subsidiaries are located outside the U.S., including Korea, Switzerland, and France, and their expenses are generally denominated in the currencies of the jurisdictions in which they conduct operations. Our results of current and future operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates. We experience fluctuations in net loss as a result of transaction gains or losses related to remeasuring certain assets and liability balances that are denominated in foreign currencies. These exposures may change over time as business practices evolve and economic conditions change. To date, foreign currency transaction gains and losses have not been material to our consolidated financial statements, and OSR Holdings has not engaged in any foreign currency hedging transactions. Segments OSR Holdings operates and manages the business as one reportable and operating segment, which is the business of a global healthcare holding company creating, acquiring and developing pharmaceutical and healthcare technologies. Our chief executive officer